## **REMARKS TO THE SPECIFICATION**

The paragraph beginning on page 42, line 26 was amended to append the SEQ ID NOs assigned to the two motif sequences disclosed within this paragraph in the substitute Sequence Listing, "SEQ ID NO: 5" and "SEQ ID NO: 6". No new matter has been added.

The paragraph beginning on page 43, line 1 was amended to append the SEQ ID NOs assigned to the two motif sequences disclosed within this paragraph in the substitute Sequence Listing, "SEQ ID NO: 7" and "SEQ ID NO: 8". No new matter has been added.

## REMARKS TO THE SEQUENCE LISTING

Support for the amendments to the Sequence Listing may be found by reference to the Specification, as originally filed, and in the Sequence Listing, as originally submitted.

Support for the newly added sequences, SEQ ID NO: 5 and SEQ ID NO: 6, and SEQ ID NO: 7 and SEQ ID NO: 8, may be found in the Specification as originally filed, and specifically, on page 42 and 43, respectively. These sequences were added to the Sequence Listing, along with the appropriate lines <221> thru <223>, to conform to 37 C.F.R. 1.821-1.825.

Applicants make the statement that the contents of the Substitute paper and computer readable copies of the Sequence Listing submitted concurrently herewith are the same. Applicants also make the statement that no new matter is believed to be added. The Substitute paper and computer readable copies of the Sequence Listing are believed to comply with the requirements of 37 C.F.R. 1.821 through 1.825.

If any fee is due in connection herewith not already accounted for, please charge such fee to Deposit Account No. 19-3880 of the undersigned.

Respectfully submitted,

Attorney for Applicants

Reg. No. 22,076

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000 (609) 252-4336

Date: December 20, 2004